武汉市星熠艾克生物医药有限责任公司
-
产品名称： Afatinib Cas No.： 439081-18-2 规格:： 纯度：99% 价格： 550元/10mg元/ 发布日期:： 2016-12-02 Introduction: Afatinib is a candidate drug against non-small cell lung carcinoma, developed by Boehringer Ingelheim. As of December 2008, it is undergoing a Phase III clinical trial for this indication, and Phase II trials for breast, prostate, and head and neck cancers, as well as glioma. In October 2010 a new Boehringer Ingelheim Phase III trial called "Lux-Lung 5" began with this drug.Fall 2010 interim results suggest the drug extended progression-free survival threefold compared to placebo, but did not extend overall survival.
CAS Number: 439081-18-2
Name: N-[4-[(3-Chloro-4-fluorophenyl)amino]-7-[[(3S)-tetrahydro-3-furanyl]oxy]-6-quinazolinyl]-4-(dimethylamino)-2-butenamide
Formula: C24H25ClFN5O3
Molecular Weight: 485.94
Deleted CAS: 915958-11-1
Synonyms: Tovok;BIBW 2992;
Density: 1.380 g/cm3
Boiling Point: 676.917 °C at 760 mmHg
Flash Point: 363.186 °C
声明：以上信息未经本网证实,仅供参考,华夏化工网不承担任